Peritoneal Neoplasms
Information
- Disease name
- Peritoneal Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02571725 | Active, not recruiting | Phase 1/Phase 2 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | February 23, 2016 | July 15, 2027 |
| NCT01932125 | Active, not recruiting | Phase 4 | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | December 5, 2018 | June 21, 2025 |
| NCT03740165 | Active, not recruiting | Phase 3 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | December 18, 2018 | May 29, 2026 |
| NCT05257408 | Active, not recruiting | Phase 3 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | June 29, 2022 | June 2025 |
| NCT04498117 | Active, not recruiting | Phase 3 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | August 25, 2020 | August 26, 2027 |
| NCT00103545 | Completed | Phase 1/Phase 2 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | July 2003 | August 2004 |
| NCT00112086 | Completed | Phase 2 | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | January 2003 | February 2007 |
| NCT00183794 | Completed | Phase 2 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | November 2002 | May 2010 |
| NCT00189345 | Completed | Phase 2 | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | May 2004 | October 2005 |
| NCT00191607 | Completed | Phase 3 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | July 2002 | November 2005 |
| NCT00191646 | Completed | Phase 3 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | October 2002 | August 2009 |
| NCT00216372 | Completed | Phase 3 | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | September 2003 | October 2008 |
| NCT00262990 | Completed | Phase 3 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | November 2005 | |
| NCT00001332 | Completed | Phase 1 | Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis | December 1992 | October 2000 |
| NCT00317772 | Completed | Phase 1/Phase 2 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | September 2, 2004 | November 4, 2020 |
| NCT00318370 | Completed | Phase 2 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | May 2006 | June 2010 |
| NCT00332696 | Completed | Phase 2 | Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | September 2005 | September 2008 |
| NCT00382811 | Completed | Phase 3 | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | October 2006 | April 2011 |
| NCT00436657 | Completed | Phase 1 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | February 2007 | April 2011 |
| NCT00443196 | Completed | Phase 2/Phase 3 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | March 2006 | September 2010 |
| NCT00502177 | Completed | Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin | June 19, 2007 | August 29, 2018 | |
| NCT03593681 | Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | August 27, 2018 | February 14, 2020 | |
| NCT00517621 | Completed | Phase 2 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | February 2006 | October 2010 |
| NCT00666991 | Completed | Phase 1 | Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers | July 2008 | May 2013 |
| NCT00698451 | Completed | Phase 2 | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | August 2008 | October 2010 |
| NCT01015118 | Completed | Phase 3 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | November 17, 2009 | September 15, 2016 |
| NCT03287375 | Completed | Phase 2 | Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy - | December 1, 2016 | October 1, 2022 |
| NCT01314105 | Completed | Phase 1 | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer | March 2011 | April 2016 |
| NCT01384253 | Completed | Phase 1 | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | July 2011 | July 2016 |
| NCT01462890 | Completed | Phase 3 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | November 2011 | December 2021 |
| NCT01478685 | Completed | Phase 1 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | November 29, 2011 | November 17, 2015 |
| NCT03246321 | Completed | Phase 2 | PIPAC for Peritoneal Metastases of Colorectal Cancer | October 1, 2017 | October 1, 2019 |
| NCT01697488 | Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA) | February 2, 2012 | September 27, 2019 | |
| NCT01846611 | Completed | Phase 3 | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | October 16, 2013 | November 16, 2018 |
| NCT02082886 | Completed | HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry | February 2014 | January 2020 | |
| NCT02231086 | Completed | Phase 3 | Adjuvant HIPEC in High Risk Colon Cancer | March 2015 | June 1, 2019 |
| NCT03038100 | Completed | Phase 3 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 8, 2017 | August 12, 2022 |
| NCT02578888 | Completed | N/A | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | April 2015 | April 2019 |
| NCT02638051 | Completed | Phase 2 | Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT | January 2014 | December 2015 |
| NCT02658214 | Completed | Phase 1 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | April 28, 2016 | November 14, 2019 |
| NCT02786524 | Completed | N/A | Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy | February 15, 2016 | October 31, 2017 |
| NCT02903771 | Completed | Phase 1 | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | November 2016 | March 24, 2020 |
| NCT00035100 | Completed | Phase 2 | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | September 2001 | |
| NCT00063401 | Completed | Phase 2 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | September 2003 | June 2006 |
| NCT00074867 | Completed | Phase 2 | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | October 2003 | September 2004 |
| NCT00086567 | Completed | Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | December 12, 2005 | ||
| NCT06351475 | Not yet recruiting | N/A | Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy | September 2024 | October 2026 |
| NCT05353582 | Not yet recruiting | Phase 2 | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | June 1, 2022 | July 1, 2025 |
| NCT04111978 | Recruiting | Phase 3 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | November 5, 2020 | October 1, 2030 |
| NCT05617755 | Recruiting | Phase 1 | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | November 29, 2022 | February 2027 |
| NCT05185947 | Recruiting | Phase 2 | Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | October 13, 2022 | December 30, 2031 |
| NCT05194072 | Recruiting | Phase 1 | A Study of SGN-B7H4V in Advanced Solid Tumors | January 12, 2022 | January 31, 2027 |
| NCT02758951 | Recruiting | Phase 2/Phase 3 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | June 1, 2017 | August 1, 2026 |
| NCT06223763 | Recruiting | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery | January 1, 2024 | June 1, 2024 | |
| NCT03976999 | Recruiting | N/A | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | July 5, 2017 | January 2027 |
| NCT00407407 | Terminated | Phase 1 | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | November 1, 2006 | February 1, 2008 |
| NCT01681368 | Terminated | Phase 2 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | August 15, 2012 | April 30, 2014 |
| NCT00516841 | Terminated | Phase 2 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | August 2007 | April 2008 |
| NCT00445549 | Terminated | Phase 2 | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | January 2007 | October 2009 |
| NCT00352755 | Terminated | Phase 2 | A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis | May 2006 | April 2009 |
| NCT00288275 | Terminated | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | July 2004 | October 2012 | |
| NCT02478476 | Unknown status | DNA Single Nucleotide Polymorphisms as Predictors of Toxicity | July 2015 | December 2017 | |
| NCT03150992 | Unknown status | N/A | EDMONd - Elemental Diet in Bowel Obstruction | July 19, 2017 | December 2019 |
| NCT01225757 | Withdrawn | N/A | Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC | November 2010 | August 31, 2011 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010534